A landmark study published in Molecular Psychiatry on April 20, 2026, is raising important questions about the safety of certain widely used medications during pregnancy. Researchers at the University of Nebraska Medical Center (UNMC) analyzed 6.14 million maternal-child health records — representing nearly one-third of all U.S. births between 2014 and 2023 — and found a consistent association between prenatal exposure to a specific class of medications and an increased risk of autism spectrum disorder (ASD) in children. The findings are significant, nuanced, and carry an urgent message for both expectant mothers and the medical professionals who care for them.
What Are Sterol Biosynthesis–Inhibiting Medications?
At the heart of this study is a class of drugs the researchers call sterol biosynthesis–inhibiting medications, or SBIMs. What makes this study different from prior research is its approach: rather than grouping medications by what they treat, the UNMC team grouped them by a shared biochemical effect — their ability to interfere with the body’s cholesterol synthesis pathway.
These sterol biosynthesis–inhibiting medications include certain antidepressants, antipsychotics, anxiolytics, beta-blockers, and statins. The 14 specific medications studied include aripiprazole, atorvastatin, bupropion, buspirone, fluoxetine, haloperidol, metoprolol, nebivolol, pravastatin, propranolol, rosuvastatin, sertraline, simvastatin, and trazodone. Many of these are among the most commonly prescribed medications in the United States, collectively accounting for more than 400 million annual prescriptions.
These are not obscure drugs. Sertraline, fluoxetine, and bupropion are among the most frequently prescribed antidepressants in the country. Statins like atorvastatin and simvastatin are taken daily by tens of millions of adults for heart health. The fact that this research implicates such widely used medications makes its findings all the more consequential.
Why Cholesterol Matters for the Developing Brain
To understand why disrupting the cholesterol pathway during pregnancy matters, it helps to understand the role cholesterol plays in fetal development. Cholesterol is essential for fetal development, especially for the brain, the most cholesterol-rich organ in the body. The fetal brain begins producing its own sterols around 19 to 20 weeks of gestation.
When this pathway is disrupted, the consequences can be severe. Genetic disruptions in this pathway are known to cause serious developmental syndromes such as Smith-Lemli-Opitz syndrome (SLOS), in which up to 75 percent of children meet criteria for ASD. The researchers’ central argument is that many widely used medications can unintentionally produce a similar — though less severe — disruption in the same biological pathway during the most critical window of fetal brain development.
The Statistics: A Dose-Dependent Risk
The study’s findings are both statistically striking and clinically meaningful, particularly because the risk appears to increase with each additional medication added.
Mothers prescribed at least one SBIM during pregnancy had a 1.47-fold higher risk of having a child diagnosed with ASD. The risk increased in a dose-dependent manner: for each additional SBIM co-prescribed, the risk increased by 1.33-fold, reaching 2.33-fold when four or more SBIMs were prescribed simultaneously.
Among the 196,447 children diagnosed with ASD in the cohort, 14.2 percent had prenatal SBIM exposure. And perhaps most alarming from a public health standpoint, use of SBIMs during pregnancy increased sharply over time — rising from 4.3 percent of pregnancies in 2014 to 16.8 percent in 2023. That is nearly a fourfold increase in less than a decade, meaning the population of children with prenatal exposure to these medications is growing rapidly.
A Critical Clarification: Do Not Stop Medications Without Medical Guidance
The researchers are explicit and emphatic on one point that every reader needs to understand clearly. The authors stress that no pregnant patient should discontinue or alter medication without medical supervision, as many SBIMs are essential and often life-saving treatments. Senior author Karoly Mirnics, MD, PhD, dean and director of the UNMC Munroe-Meyer Institute, stated that the findings do not suggest these medications are unsafe for adults, but that they raise important questions about their use during pregnancy — a period when even small biochemical disruptions may have outsized effects on fetal brain development.
This distinction matters enormously. For many pregnant women, medications like antidepressants or beta-blockers are not optional — they are medically necessary. The goal of this research is not to alarm patients into stopping treatment, but to prompt a careful, individualized conversation between patients and their providers about risks, benefits, and safer alternatives when available.
What the Researchers Are Recommending
The study calls for a re-evaluation of prescribing practices and for the development of safer alternatives for use during pregnancy. Specific recommendations include creating a comprehensive list of medications with sterol-inhibiting effects, evaluating all new pharmaceuticals for unintended sterol pathway inhibition, increasing provider education about medication-associated sterol disruption during pregnancy, discussing safer alternatives when discontinuing treatment is not possible, avoiding prescribing multiple SBIMs for pregnant women whenever feasible, and identifying patients with genetic vulnerabilities in sterol metabolism who may be particularly sensitive to SBIM effects.
Takeaway
This study is one of the most significant pieces of autism research to emerge in recent years, precisely because it shifts attention toward a modifiable risk factor — one that exists in the prescribing decisions made during pregnancy. For families touched by autism, and for the clinicians and therapists who work alongside them, the message is clear: the causes of autism are complex, multifactorial, and still being uncovered, and this research adds an important new dimension to that understanding. Pregnant women should not panic, and they should absolutely not stop any prescribed medication without speaking to their doctor first. But they should feel empowered to ask questions, discuss alternatives, and ensure that every medication taken during pregnancy has been carefully considered in light of the latest evidence. This study makes that conversation more important than ever.
Source: Read the Original Article
You can reach me at my website or call me directly at 832-559-3520 if you have any questions. Thank You!
- Is Social Media Really an Addiction? What Science Says - April 20, 2026
- New Study Raises Concerns About Pregnancy Medications - April 20, 2026
- Big Tech Faces Children’s Addiction Claims in Court - March 23, 2026
